NCT07062549View on ClinicalTrials.gov

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Renal Cell Carcinoma (Kidney Cancer)
Interventions
DRUG

111In-XYIMSR-01

Unite Dose: 10.5±1 mCi of 111In-XYIMSR-01 Route of administration: Intravenous catheter placed in an antecubital vein or an equivalent venous access

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER